Advaxis PE Ratio 2007-2021 | ADXS

Current and historical p/e ratio for Advaxis (ADXS) from 2007 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Advaxis PE ratio as of October 15, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Advaxis PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-10-15 0.47 0.00
2021-07-31 0.41 $-0.19 0.00
2021-04-30 0.49 $-0.26 0.00
2021-01-31 0.73 $-0.32 0.00
2020-10-31 0.34 $-0.42 0.00
2020-07-31 0.58 $-0.49 0.00
2020-04-30 0.67 $-1.40 0.00
2020-01-31 0.86 $-2.89 0.00
2019-10-31 0.32 $-0.04 0.00
2019-07-31 0.56 $-4.24 0.00
2019-04-30 3.54 $-7.29 0.00
2019-01-31 5.69 $-9.75 0.00
2018-10-31 8.42 $-19.79 0.00
2018-07-31 21.90 $-23.99 0.00
2018-04-30 24.00 $-31.93 0.00
2018-01-31 44.40 $-35.53 0.00
2017-10-31 51.00 $-34.63 0.00
2017-07-31 97.05 $-34.33 0.00
2017-04-30 128.40 $-29.54 0.00
2017-01-31 134.40 $-28.64 0.00
2016-10-31 121.35 $-31.03 0.00
2016-07-31 125.10 $-28.34 0.00
2016-04-30 116.10 $-27.74 0.00
2016-01-31 102.30 $-28.79 0.00
2015-10-31 166.35 $-24.89 0.00
2015-07-31 249.90 $-19.34 0.00
2015-04-30 252.15 $-17.24 0.00
2015-01-31 147.75 $-11.69 0.00
2014-10-31 47.70 $-12.29 0.00
2014-07-31 42.60 $-26.84 0.00
2014-04-30 40.80 $-27.89 0.00
2014-01-31 67.35 $-44.38 0.00
2013-10-31 56.10 $-63.57 0.00
2013-07-31 52.50 $-57.12 0.00
2013-04-30 131.25 $-69.42 0.00
2013-01-31 131.25 $-50.68 0.00
2012-10-31 93.75 $-25.94 0.00
2012-07-31 131.25 $-17.84 0.00
2012-04-30 243.75 $18.74 13.01
2012-01-31 281.25 $-74.96 0.00
2011-10-31 262.50 $-74.96 0.00
2011-07-31 281.25 $-83.06 0.00
2011-04-30 393.75 $-83.06 0.00
2011-01-31 281.25 $-120.54 0.00
2010-10-31 281.25 $-176.76 0.00
2010-07-31 318.75 $-149.92 0.00
2010-04-30 412.50 $-168.67 0.00
2010-01-31 262.50 $-56.22 0.00
2009-10-31 243.75 0 0.00
2009-07-31 168.75 $-37.48 0.00
2009-04-30 93.75 $-37.48 0.00
2009-01-31 75.00 $-18.74 0.00
2008-10-31 75.00 $-18.74 0.00
2008-07-31 112.50 0 0.00
2008-04-30 281.25 0 0.00
2008-01-31 281.25 0 0.00
2007-10-31 375.00 0 0.00
2007-07-31 468.75 0 0.00
2007-04-30 637.50 0 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.069B $0.000B
Advaxis, Inc. is a development stage biotechnology company focused on developing safe and effective cancer vaccines that utilize multiple mechanisms of immunity. The Company is developing a live Listeria vaccine technology under license from the University of Pennsylvania which secretes a protein sequence containing a tumor-specific antigen. The Company believes this vaccine technology is capable of stimulating the body's immune system to process and recognize the antigen as if it were foreign, generating an immune response able to attack the cancer. It also considers this to be a broadly enabling platform technology that can be applied to the treatment of many types of cancers, infectious diseases and auto-immune disorders. The Company's products in development include Lovaxin C and Lovaxin B, Lovaxin P.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00